Indeed, preclinical investigations have demonstrated that, compared to their SLC7A11-low counterparts, SLC7A11-high cancer cells and tumors manifest heightened sensitivity to inhibitors of glucose transporters (GLUTs) (Joly et al., 2020; Liu et al., 2020b, 2023a). This evidence concerns the gene SLC7A11 and cancer.